Altravax Inc. in Fargo, North Dakota received two grants from National Institutes of Health (NIH) for research on vaccines for HIV-1. A third NIH grant supports the company’s work on vaccines for an influenza virus. All three grants, valued at $1.8 million, are awarded under NIH’s Small Business Innovation Research (SBIR) program.
Two of the SBIR grants totaling $1.2 million were awarded by NIH’s National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1. Altravax says it will use its MolecularBreeding technology to create vaccines that provide protection against the various strains of HIV-1. The existence of a large number of virus strains and the changing nature of the virus is one of the major challenges facing the development of vaccines for HIV/AIDS.
Altravax also received a third NIH SBIR grant for $600,000 to support its research on vaccines that provide protection against the two influenza B virus strains that co-circulate each flu season.
You must be logged in to post a comment.